# ASC - Autism Study

> **NCT05602116** · PHASE1 · COMPLETED · sponsor: **Cell to Cure ApS** · enrollment: 10 (actual)

## Conditions studied

- Autism Spectrum Disorder
- Gastrointestinal Dysfunction
- Leaky Gut Syndrome
- Mesenchymal Stromal Cells
- Inflammatory Bowel Diseases

## Interventions

- **DRUG:** Adipose tissue derived mesenchymal stromal/stem cells (Cell2Cure®)

## Key facts

- **NCT ID:** NCT05602116
- **Lead sponsor:** Cell to Cure ApS
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-06-09
- **Primary completion:** 2024-06-28
- **Final completion:** 2024-09-20
- **Target enrollment:** 10 (ACTUAL)
- **Last updated:** 2024-09-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05602116

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05602116, "ASC - Autism Study". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05602116. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*